Prior to investing into a fund, please read the relevant key information document which contains important information about the fund. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. This website does not contain any personal recommendations for a particular course of action, service or product. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. To read this article on click here.Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. (AVIR) : Free Stock Analysis ReportĪkero Therapeutics, Inc. Roche Holding AG (RHHBY) : Free Stock Analysis Reportīlueprint Medicines Corporation (BPMC) : Free Stock Analysis ReportĪtea Pharmaceuticals, Inc. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. AVIR delivered a negative earnings surprise of 58.74% on average. BPMC (49.30) is undervalued by 5.78 relative to our estimate of its Fair Value price of 52. View analysts price targets for BPMC or view top-rated stocks among Wall Street analysts. This suggests a possible upside of 50.4 from the stock's current price. On average, they expect the company's stock price to reach 76.20 in the next twelve months. Loss per share estimates for Atea Pharmaceuticals narrowed 10.9% for 2022 and 9.5% for 2023 in the past 60 days.Įarnings of Atea Pharmaceuticals surpassed estimates in three of the trailing four quarters and missed on the other occasion. Their BPMC share price forecasts range from 38.00 to 114.00. AKRO delivered an earnings surprise of 7.66% on average. Physical State : Liquid Classification : Insecticide Form : Liquid Price : 200 INR/Kilograms Minimum Order Quantity : 4. Loss per share estimates for Akero Therapeutics narrowed 6.9% for 2022 and 4.8% for 2023 in the past 60 days.Įarnings of Akero Therapeutics surpassed estimates in three of the trailing four quarters and missed on the other occasion. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. AVIR, both sporting a Zacks Rank #2 (Buy) at present. Some better-ranked stocks in the biotech sector are Akero Therapeutics, Inc. Research and development expenses were $128 million, up 51.6% from the year-ago figure, owing to higher costs associated with clinical studies and increased costs due to early discovery efforts.īlueprint Medicines Corporation Price, Consensus and EPS Surpriseīlueprint Medicines Corporation price-consensus-eps-surprise-chart | Blueprint Medicines Corporation Quote Zacks Rank & Stocks to Considerīlueprint Medicines currently carries a Zacks Rank #3 (Hold). The year-over-year surge in total revenues can be attributed to license revenues. License revenues from the related party were $27.5 million in the third quarter of 2022. The average Blueprint Medicines stock price prediction forecasts a potential upside of 51.42 from the current BPMC share price of 49.29. that Blueprint Medicines's share price could reach 74.64 by Aug 7, 2024. Sales of the drug grew slightly on a sequential basis and 65.8% on a year-over-year basis.Ĭollaboration revenues were $9.8 million, primarily generated from the agreements with CStone Pharmaceutical and Roche. On average, Wall Street analysts predict. Net product revenues from Ayvakit sales were $28.6 million. RHHBY reported Gavreto product sales of 20 million CHF in the year-to-date period.īlueprint Medicines’ total revenues of $66 million comprised net product revenues from Ayvakit (avapritinib) sales, collaboration revenues and license revenues-related party. product sales of Gavreto (pralsetinib) to Roche RHHBY on Jul 1, 2021, Blueprint Medicines only records its share of profits for the drug in its financial results.īlueprint Medicines and Roche are co-developing Gavreto, which has been approved for treating patients with various types of RET-altered thyroid cancers and other solid tumors. The real example is that we import Weedicide Ceypetco Glyphosate and. Since the company has transferred the responsibilities of booking U.S. Therefore, Ceypetco Agrochemicals act as a price controller in the Agrochemicals Market. Image Source: Zacks Investment Research Quarter in Detail
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |